Summary
3.09 -0.02(-0.64%)10/17/2024
OncoCyte Corp (OCX)
OncoCyte Corp (OCX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.64 | 1.31 | -0.64 | -6.36 | 19.77 | 1.64 | 81.76 | -61.76 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 3.09 | |
| Open | 3.03 | |
| High | 3.26 | |
| Low | 3.01 | |
| Volume | 10,405 | |
| Change | -0.02 | |
| Change % | -0.64 | |
| Avg Volume (20 Days) | 28,243 | |
| Volume/Avg Volume (20 Days) Ratio | 0.37 | |
| 52 Week Range | 2.08 - 4.34 | |
| Price vs 52 Week High | -28.80% | |
| Price vs 52 Week Low | 48.56% | |
| Range | 1.98 | |
| Gap Up/Down | -0.23 | |
Fundamentals | ||
| Market Capitalization (Mln) | 40 | |
| EBIDTA | -15,727,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 8.40 | |
| Book Value | 1.0780 | |
| Earnings Per Share | -0.4170 | |
| EPS Estimate Current Quarter | -0.1200 | |
| EPS Estimate Next Quarter | -0.1000 | |
| EPS Estimate Current Year | -0.4400 | |
| EPS Estimate Next Year | -0.4400 | |
| Diluted EPS (TTM) | -0.4170 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -8.4428 | |
| Return on asset (TTM) | -0.2166 | |
| Return on equity (TTM) | -0.5153 | |
| Revenue TTM | 4,641,000 | |
| Revenue per share TTM | 0.0560 | |
| Quarterly Revenue Growth (YOY) | 0.7730 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -639,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.0795 | |
| Revenue Enterprise Value | 36.3201 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 92,231,400 | |
| Shares Float | 53,212,928 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 10.24 | |
| Institutions (%) | 62.43 | |
10/16 16:16 EST - prismmediawire.com
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
IRVINE, Calif., Oct. 16, 2024 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles.
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
IRVINE, Calif., Oct. 16, 2024 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles.
10/16 16:15 EST - globenewswire.com
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles.
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles.
10/13 09:45 EST - 247wallst.com
Insider Buying Slows, but Not for 7 These Buyers
24/7 Wall St. Insights Insider buying slowed to a trickle ahead of the third-quarter earnings reporting season.
Insider Buying Slows, but Not for 7 These Buyers
24/7 Wall St. Insights Insider buying slowed to a trickle ahead of the third-quarter earnings reporting season.
10/08 08:31 EST - prismmediawire.com
Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
IRVINE, Calif., October 8, 2024 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test, DetermaIO™.
Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
IRVINE, Calif., October 8, 2024 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test, DetermaIO™.
10/02 19:13 EST - prismmediawire.com
Oncocyte Signs Leading Transplant Centers in US and Germany
IRVINE, Calif., Oct. 02, 2024 – PRISM MediaWire – Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers include two leading transplant university hospitals in the U.S. and Germany.
Oncocyte Signs Leading Transplant Centers in US and Germany
IRVINE, Calif., Oct. 02, 2024 – PRISM MediaWire – Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers include two leading transplant university hospitals in the U.S. and Germany.
10/02 19:12 EST - prismmediawire.com
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories IRVINE, Calif., Oct. 02, 2024 – Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with new and existing investors, including Bio-Rad Laboratories, Inc.
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories IRVINE, Calif., Oct. 02, 2024 – Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with new and existing investors, including Bio-Rad Laboratories, Inc.
08/12 16:30 EST - prismmediawire.com
Oncocyte's VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., August 12, 2024 — Oncocyte Corp.
Oncocyte's VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., August 12, 2024 — Oncocyte Corp.
08/10 13:00 EST - seekingalpha.com
OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript
OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript
OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript
OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript
08/08 16:05 EST - prismmediawire.com
Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results
Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., August 8, 2024 (GLOBE NEWSWIRE) — Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders.
Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results
Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., August 8, 2024 (GLOBE NEWSWIRE) — Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders.
08/05 16:06 EST - prismmediawire.com
Oncocyte Announces August Investor Conferences Participation
IRVINE, Calif., August 5, 2024 — Oncocyte Corp.
Oncocyte Announces August Investor Conferences Participation
IRVINE, Calif., August 5, 2024 — Oncocyte Corp.
08/01 16:07 EST - prismmediawire.com
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
Conference Call and Webcast on Thursday, August 8, 2024 at 2:00 p.m. PT / 5:00 p.m.
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
Conference Call and Webcast on Thursday, August 8, 2024 at 2:00 p.m. PT / 5:00 p.m.
07/11 08:02 EST - prismmediawire.com
MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in “Take Advantage of the Moment” Episode
HOLLAND, Mich., July 11, 2024 – MedTech Gurus, a leading podcast focused on the forefront of medical technology, featured Oncocyte Corporation (NASDAQ: OCX) CEO Josh Riggs in its latest episode, “Take Advantage of the Moment.
MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in “Take Advantage of the Moment” Episode
HOLLAND, Mich., July 11, 2024 – MedTech Gurus, a leading podcast focused on the forefront of medical technology, featured Oncocyte Corporation (NASDAQ: OCX) CEO Josh Riggs in its latest episode, “Take Advantage of the Moment.
06/24 12:41 EST - globenewswire.com
Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics company, Oncocyte's (Nasdaq: OCX) appointment of leading finance executive, Andrea James, as Chief Financial Officer. This strategic move comes at a pivotal time as Oncocyte prepares for significant commercial and regulatory milestones expected in 2024 and 2025.
Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics company, Oncocyte's (Nasdaq: OCX) appointment of leading finance executive, Andrea James, as Chief Financial Officer. This strategic move comes at a pivotal time as Oncocyte prepares for significant commercial and regulatory milestones expected in 2024 and 2025.
06/17 16:05 EST - prismmediawire.com
Oncocyte Appoints Andrea James as Chief Financial Officer
IRVINE, Calif., June 17, 2024 – Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer.
Oncocyte Appoints Andrea James as Chief Financial Officer
IRVINE, Calif., June 17, 2024 – Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer.